These therapeutic effects were mediated by inhibiting the NF-κB-STAT3 signaling pathway and RhoA/Rho-associated kinase (ROCK) activity, which controls colonic inflammation, F-actin polymerization, and plays an important role in the pathogenesis of colitis. Here, STAT3 is linked to colitis.